计算机辅助预测EGFR突变的非小细胞肺癌药物敏感性的研究进展

表皮生长因子受体(epidermal growth factor receptor，EGFR)既是非小细胞肺癌(non-small cell lung cancer，NSCLC)的常见驱动基因，也是临床上NSCLC的重要治疗靶标。但EGFR突变导致的耐药性问题严重影响了靶向药物的治疗效果，限制了精准医疗的发展。本文对目前上市的EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors，EGFR-TKIs)的靶标结合模式进行综述，旨在为新型EGFR-TKIs开发提供理论依据，并回顾总结应用计算机预测EGFR突变体的药物敏感性的研究进展，以期推动发展临床决策的辅助工具来帮助临床医师设计个性化治疗方案。

Research Progress of Computer-aided Drug Sensitivity Prediction for Non-small Cell Lung Cancer with EGFR Mutation

Epidermal growth factor receptor(EGFR) is not only a common driver gene of non-small cell lung cancer (NSCLC), but also an important therapeutic target for NSCLC in clinical practice. However, the drug resistance problem caused by EGFR mutation seriously affects the therapeutic effect of targeted drugs and limits the development of precision medicine. In this paper, the target binding mode of the currently marketed EGFR tyrosine kinase inhibitors(EGFR-TKIs) is described to provide a theoretical basis for the development of novel EGFR-TKIs. And the research progress of applying computer to predict the drug sensitivity of EGFR mutants is reviewed, with the aim of promoting the development of auxiliary clinical decision-making tools for personalized treatment planning.